Data Supplement

• Supplemental Data -

  Supplemental Appendix. Generation and characterization of mirikizumab, a humanized monoclonal antibody targeting the p19 subunit of IL-23

  Supplemental Figure 1. Assessment of Fc Receptor Activation and Complement Binding